Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 97503 | 3.44 |
09:34 ET | 119574 | 3.42 |
09:36 ET | 43393 | 3.4199 |
09:38 ET | 69454 | 3.38 |
09:39 ET | 33647 | 3.39 |
09:41 ET | 72380 | 3.385 |
09:43 ET | 45796 | 3.39 |
09:45 ET | 90251 | 3.415 |
09:48 ET | 164570 | 3.46 |
09:50 ET | 132103 | 3.48 |
09:52 ET | 347663 | 3.5 |
09:54 ET | 111605 | 3.5 |
09:56 ET | 129232 | 3.485 |
09:57 ET | 371591 | 3.47 |
09:59 ET | 60774 | 3.465 |
10:01 ET | 69019 | 3.458 |
10:03 ET | 30559 | 3.47 |
10:06 ET | 171110 | 3.42 |
10:08 ET | 11594 | 3.42 |
10:10 ET | 42764 | 3.425 |
10:12 ET | 18223 | 3.445 |
10:14 ET | 12673 | 3.43 |
10:15 ET | 7922 | 3.4337 |
10:17 ET | 83548 | 3.425 |
10:19 ET | 8987 | 3.42 |
10:21 ET | 4961 | 3.425 |
10:24 ET | 14097 | 3.42 |
10:26 ET | 77869 | 3.405 |
10:28 ET | 102674 | 3.405 |
10:30 ET | 12053 | 3.41 |
10:32 ET | 9517 | 3.405 |
10:33 ET | 8953 | 3.405 |
10:35 ET | 20386 | 3.425 |
10:37 ET | 36663 | 3.41 |
10:39 ET | 12515 | 3.395 |
10:42 ET | 44453 | 3.385 |
10:44 ET | 57831 | 3.3788 |
10:46 ET | 15595 | 3.385 |
10:48 ET | 16028 | 3.385 |
10:50 ET | 30311 | 3.4 |
10:51 ET | 31479 | 3.4 |
10:53 ET | 3024 | 3.4 |
10:55 ET | 4297 | 3.395 |
10:57 ET | 24636 | 3.38 |
11:00 ET | 37516 | 3.375 |
11:02 ET | 58763 | 3.355 |
11:04 ET | 21397 | 3.34 |
11:06 ET | 32323 | 3.355 |
11:08 ET | 62727 | 3.35 |
11:09 ET | 37327 | 3.35 |
11:11 ET | 181000 | 3.3692 |
11:13 ET | 153327 | 3.38 |
11:15 ET | 17366 | 3.375 |
11:18 ET | 6127 | 3.3771 |
11:20 ET | 20821 | 3.37 |
11:22 ET | 72517 | 3.375 |
11:24 ET | 57294 | 3.385 |
11:26 ET | 121889 | 3.395 |
11:27 ET | 14685 | 3.395 |
11:29 ET | 15638 | 3.395 |
11:31 ET | 2832 | 3.395 |
11:33 ET | 21526 | 3.385 |
11:36 ET | 1225 | 3.39 |
11:38 ET | 14986 | 3.41 |
11:40 ET | 26710 | 3.4 |
11:42 ET | 1714 | 3.405 |
11:44 ET | 7425 | 3.41 |
11:45 ET | 31900 | 3.405 |
11:47 ET | 8901 | 3.41 |
11:49 ET | 8831 | 3.405 |
11:51 ET | 188842 | 3.3921 |
11:54 ET | 14868 | 3.38 |
11:56 ET | 3779 | 3.385 |
11:58 ET | 18432 | 3.38 |
12:00 ET | 1046 | 3.38 |
12:02 ET | 5944 | 3.37 |
12:03 ET | 39793 | 3.36 |
12:05 ET | 12073 | 3.355 |
12:07 ET | 1188 | 3.355 |
12:09 ET | 7500 | 3.355 |
12:12 ET | 19893 | 3.345 |
12:14 ET | 23118 | 3.345 |
12:16 ET | 45754 | 3.35 |
12:18 ET | 1200 | 3.355 |
12:20 ET | 7071 | 3.341 |
12:21 ET | 14391 | 3.34 |
12:23 ET | 18018 | 3.33 |
12:25 ET | 3344 | 3.33 |
12:27 ET | 2267 | 3.33 |
12:30 ET | 71190 | 3.325 |
12:32 ET | 5138 | 3.3225 |
12:34 ET | 3891 | 3.3267 |
12:36 ET | 33317 | 3.3299 |
12:38 ET | 1010 | 3.32 |
12:39 ET | 3250 | 3.32 |
12:41 ET | 1472 | 3.32 |
12:43 ET | 12703 | 3.325 |
12:45 ET | 1497 | 3.32 |
12:48 ET | 2491 | 3.325 |
12:50 ET | 4400 | 3.32 |
12:52 ET | 400 | 3.32 |
12:54 ET | 1200 | 3.32 |
12:56 ET | 19110 | 3.315 |
12:57 ET | 13985 | 3.31 |
12:59 ET | 3692 | 3.315 |
01:01 ET | 37338 | 3.31 |
01:03 ET | 17211 | 3.3 |
01:06 ET | 1078 | 3.3001 |
01:08 ET | 11794 | 3.31 |
01:10 ET | 25488 | 3.31 |
01:12 ET | 55806 | 3.315 |
01:14 ET | 18748 | 3.3192 |
01:15 ET | 30819 | 3.325 |
01:17 ET | 11339 | 3.325 |
01:19 ET | 1901 | 3.325 |
01:21 ET | 6976 | 3.325 |
01:24 ET | 59152 | 3.315 |
01:26 ET | 11697 | 3.315 |
01:28 ET | 4300 | 3.315 |
01:30 ET | 215701 | 3.325 |
01:32 ET | 23826 | 3.335 |
01:33 ET | 2098 | 3.335 |
01:35 ET | 2727 | 3.335 |
01:37 ET | 62769 | 3.3399 |
01:39 ET | 61721 | 3.329 |
01:42 ET | 19070 | 3.3199 |
01:44 ET | 21837 | 3.315 |
01:46 ET | 18306 | 3.315 |
01:48 ET | 26107 | 3.315 |
01:50 ET | 20263 | 3.305 |
01:51 ET | 6453 | 3.305 |
01:53 ET | 13454 | 3.305 |
01:55 ET | 5379 | 3.305 |
01:57 ET | 29335 | 3.305 |
02:00 ET | 11930 | 3.305 |
02:02 ET | 6100 | 3.3087 |
02:04 ET | 7516 | 3.305 |
02:06 ET | 53997 | 3.305 |
02:08 ET | 2983 | 3.305 |
02:09 ET | 4000 | 3.305 |
02:11 ET | 2351 | 3.305 |
02:13 ET | 10808 | 3.305 |
02:15 ET | 42911 | 3.315 |
02:18 ET | 4257 | 3.315 |
02:20 ET | 6486 | 3.315 |
02:22 ET | 37776 | 3.305 |
02:24 ET | 98079 | 3.31 |
02:26 ET | 29086 | 3.315 |
02:27 ET | 2350 | 3.315 |
02:29 ET | 11836 | 3.31 |
02:31 ET | 72888 | 3.315 |
02:33 ET | 2000 | 3.3143 |
02:36 ET | 2725 | 3.32 |
02:38 ET | 34257 | 3.305 |
02:40 ET | 42545 | 3.315 |
02:42 ET | 50063 | 3.3013 |
02:44 ET | 900 | 3.305 |
02:45 ET | 27730 | 3.305 |
02:47 ET | 11349 | 3.3 |
02:49 ET | 3500 | 3.305 |
02:51 ET | 3500 | 3.305 |
02:54 ET | 5577 | 3.305 |
02:56 ET | 22200 | 3.3 |
02:58 ET | 42735 | 3.31 |
03:00 ET | 5124 | 3.305 |
03:02 ET | 23855 | 3.31 |
03:03 ET | 53884 | 3.315 |
03:05 ET | 39728 | 3.325 |
03:07 ET | 5710 | 3.3297 |
03:09 ET | 4156 | 3.325 |
03:12 ET | 6213 | 3.32 |
03:14 ET | 38374 | 3.335 |
03:16 ET | 106248 | 3.335 |
03:18 ET | 11118 | 3.33 |
03:20 ET | 3138 | 3.335 |
03:21 ET | 29879 | 3.325 |
03:23 ET | 2494 | 3.325 |
03:25 ET | 7400 | 3.325 |
03:27 ET | 124540 | 3.34 |
03:30 ET | 21393 | 3.345 |
03:32 ET | 117350 | 3.345 |
03:34 ET | 28317 | 3.36 |
03:36 ET | 103020 | 3.355 |
03:38 ET | 14919 | 3.355 |
03:39 ET | 87857 | 3.345 |
03:41 ET | 10088 | 3.345 |
03:43 ET | 8898 | 3.345 |
03:45 ET | 6211 | 3.34 |
03:48 ET | 53762 | 3.35 |
03:50 ET | 21113 | 3.35 |
03:52 ET | 41274 | 3.345 |
03:54 ET | 37017 | 3.345 |
03:56 ET | 140222 | 3.355 |
03:57 ET | 55737 | 3.35 |
03:59 ET | 206136 | 3.35 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.1B | -9.7x | --- |
Vera Therapeutics Inc | 2.0B | -18.2x | --- |
CG Oncology Inc | 2.2B | -28.8x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.3x | --- |
Fusion Pharmaceuticals Inc | 1.8B | -15.1x | --- |
Inhibrx Inc | 1.8B | -6.4x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.42 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -9.7x |
Price/Sales (TTM) | 3,969.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.